Study of drug PB2452 in Ticagrelor-Treated Patients with Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure

The research study is being conducted to test the study drug PB2452 to see if it is safe and will reverse the bleeding effects of Brilinta® (also known as ticagrelor). Candidates must be taking Brilinta® (ticagrelor) or show intake within the past 3 days. They will be considered for participation in the study if they are experiencing uncontrolled or life-threatening bleeding or require urgent surgery where reversal of the antiplatelet effects of the medication Brilinta® (ticagrelor) is required.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Bleeding
• Age: Between 18 Years - 99 Years
• Gender: All